Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.89 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.56 |
| ▸ | TUBB | P07437 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrocurcumin SCHEMBL29370299 | 0.94 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| Tetrahydrocurcumin SCHEMBL284877 | 0.94 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| Tetrahydrocurcumin SCHEMBL29372158 | 0.94 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| SCHEMBL6339281 | 0.94 | ALOX5 (0.77) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| SCHEMBL10307817 | 0.93 | ALOX5 (0.91) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| SCHEMBL10307534 | 0.93 | ALOX5 (0.76) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| SCHEMBL10307533 | 0.93 | ALOX5 (0.91) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| SCHEMBL10307813 | 0.93 | ALOX5 (0.76) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| SCHEMBL10307535 | 0.89 | ALOX5 (0.84) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 | |
| SCHEMBL645127 | 0.89 | ALOX5 (0.89) | ALOX5OR51E2CYP3A4CYP1A2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2517716-A1 | Oral compositions containing botanical extracts | Colgate-Palmolive Company (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120244086-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF ZINGIBER OFFICINALE AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244085-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF MYRISTICA FRAGRANS AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244087-A1 | ORAL COMPOSITIONS CONTAINING A COMBINATION OF NATURAL EXTRACTS AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120237455-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF ZIZYPHUS JOAZEIRO AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120237456-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011068815-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF ZIZYPHUS JOAZEIRO AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20090087501-A1 | Oral Compositions Containing Botanical Extracts | COLGATE-PALMOLIVE COMPANY (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090087501-A1 | Oral Compositions Containing Botanical Extracts | COLGATE-PALMOLIVE COMPANY (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244087-A1 | ORAL COMPOSITIONS CONTAINING A COMBINATION OF NATURAL EXTRACTS AND RELATED METHODS | GANC, DNM1, LIPC | ALOX5 94/4885OR51E2 222/4885CYP3A4 678/4885 |
| US-20090087501-A1 | Oral Compositions Containing Botanical Extracts | MAVS, OPA1, OGG1 | ALOX5 394/4885OR51E2 3305/4885CYP3A4 1723/4885 |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP3A4 3294/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP3A4 3294/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP3A4 3294/4885 |
| US-20120237456-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS | GLA, ALPP, LIPA | ALOX5 831/4885OR51E2 3164/4885CYP3A4 1537/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP3A4 3294/4885 |
| US-20120244086-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF ZINGIBER OFFICINALE AND RELATED METHODS | SI, FABP2, ALPI | ALOX5 148/4885OR51E2 880/4885CYP3A4 335/4885 |
| US-20120237455-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF ZIZYPHUS JOAZEIRO AND RELATED METHODS | ALPP, HBZ, ZYX | ALOX5 133/4885OR51E2 515/4885CYP3A4 129/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP3A4 3294/4885 |
| US-20120244085-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF MYRISTICA FRAGRANS AND RELATED METHODS | DNM1, MARCKS, DNM2 | ALOX5 263/4885OR51E2 3398/4885CYP3A4 2570/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALOX5 2867/4885OR51E2 130/4885CYP3A4 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.